Results 71 to 80 of about 28,006 (307)
This review explains how biomaterials and nanoparticles can be used to induce or modulate tertiary lymphoid structures (TLSs), which are ectopic immune hubs that form in nonlymphoid tissues during chronic disease and cancer. By comparing different methods, the article highlights design principles for modeling TLSs or recapitulating specific TLS ...
Shaza Karaman, Mei ElGindi, Jeremy Teo
wiley +1 more source
One patient with Sjogren’s syndrome presenting schizophrenia-like symptoms
Ching-En Lin1,2 1Department of Psychiatry, Taipei Tzu-Chi Hospital, Buddhist Medical Foundation, Taiwan, Republic of China; 2School of Medicine, Tzu-Chi University, Hualien, Taiwan, Republic of China Abstract: Comorbid depression in patients with ...
Lin C
doaj
Sjögren’s syndrome-associated microRNAs in CD14+ monocytes unveils targeted TGFβ signaling [PDF]
SjS-associated miRNA expression levels are positively associated in CD14+ monocytes. Linear regression analyses were used to define associations between miRNAs in HC (circle, n = 17), SLE (triangle, n = 17), and RA (diamond, n = 18) patient groups ...
Adrienne E. G. Williams +7 more
core +4 more sources
A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen +14 more
wiley +1 more source
Sjogren′s syndrome (SS) is a chronic autoimmune disease characterized by the lymphocytic infiltration of salivary and lacrimal glands leading to xerostomia and keratoconjunctivitis sicca.
Mallika Kishore +5 more
doaj +1 more source
Consumed by Abdominal Distention
Arthritis Care &Research, EarlyView.
Abimbola Fadairo‐Azinge +3 more
wiley +1 more source
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley +1 more source
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Alex Hlavaty +4 more
wiley +1 more source
The tetrahydrobiopterin-dependent degradation of ether lipids by alkylglycerol monooxygenase (AGMO) produces fatty aldehydes, which are toxic to cells.
Keller Markus A. +4 more
doaj +1 more source

